What We're Reading: Page 145
Industry reads hand-picked by our editors
Jul 20, 2021
-
The New York Times
How an Unproven Alzheimer’s Drug Got Approved
-
The Wall Street Journal
Opioid Settlement of $26 Billion Between Drug Companies, States Expected This Week
-
FierceBiotech
Gilead hires Arcus CMO, puts him in charge of pact with biotech
-
STAT
States are sitting on millions of surplus Covid-19 vaccine doses
Jul 19, 2021
Jul 16, 2021
Jul 15, 2021
-
STAT
Woodcock: FDA may have misstepped before Alzheimer’s drug approval
-
Bloomberg
Moderna's Next Act Is Using mRNA vs. Flu, Zika, HIV, and Cancer
-
Axios
Dems hatch plan to pay for soft infrastructure with renegotiated drug prices
-
BioPharma Dive
A cancer drug startup banks new funds for NK cell therapy
Jul 14, 2021
-
CNN
Biden in standoff with Democratic senators over who should lead FDA
-
JAMA
Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective
-
The Washington Post
Biden to pick former West Virginia health official as nation’s drug czar
-
Reuters
Illumina, Grail deal faces full-scale EU antitrust probe
Jul 13, 2021
Jul 12, 2021
-
The Washington Post
Pfizer expected to brief U.S. officials in coming days on the need for a booster shot
-
The Wall Street Journal
Biogen Alzheimer’s Drug Will Exceed the $56,000 List Price for Many, Analysis Says
-
The New York Times
How Much Longer Can Martin Shkreli Control a Pharma Firm From Prison?
Previous
